The SAB-142 Phase 3 SAFEGUARD registrational study has activated 60+ clinical sites, and enrollment remains on track for completion in Q4 2026. Topline data are now expected in 2H 2027, supporting continued trial progress but offering no near-term efficacy readout.
The SAB-142 Phase 3 SAFEGUARD registrational study has activated 60+ clinical sites, and enrollment remains on track for completion in Q4 2026. Topline data are now expected in 2H 2027, supporting continued trial progress but offering no near-term efficacy readout.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
